Ocugen
-
Malvern-Based Ocugen’s Pandemic Pivot Boosts Its Stock Price by Nearly 800 Percent
The decision to expand beyond gene therapy and sign a deal to co-develop a COVID-19 vaccine has turned out well for Malvern-based Ocugen, writes John…
-
Malvern-Based Ocugen’s Stock Nearly Triples After Inking Pact to Co-Develop COVID-19 Vaccine
Malvern-based Ocugen saw its stock nearly triple last week after the company signed a letter of intent with Bharat Biotech to co-develop the India-based company’s…
-
Malvern’s Ocugen Finalizes Reverse Merger, Begins ‘New Chapter’ as a Publicly Traded Company
Ocugen, a gene therapy and biopharmaceutical company in Malvern, has finalized its reverse merger with Histogenics, a publicly traded company in Boston, and is now…
-
Malvern-Based Ocugen Enters Merger Agreement with Company in Boston
Malvern-based Ocugen, a gene therapy and biopharmaceutical company that develops new treatments for rare and underserved eye diseases, has entered into a merger agreement with…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
